Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
31 Jan 2024
Historique:
accepted: 21 01 2024
received: 11 07 2023
revised: 17 01 2024
medline: 31 1 2024
pubmed: 31 1 2024
entrez: 31 1 2024
Statut: aheadofprint

Résumé

Working groups of the European Leukemia Net (ELN) have published several important consensus guidelines. Acute lymphoblastic leukemia (ALL) has many different clinical and biological subgroups and the knowledge on disease biology and therapeutic options is increasing exponentially. The European Working Group for Adult ALL has therefore summarized the current state of the art and provided comprehensive consensus recommendations for diagnostic approaches, biologic and clinical characterization, prognostic factors and risk stratification as well as definitions of endpoints and outcomes. Aspects of treatment, management of subgroups and specific situations, aftercare and supportive care are covered in a separate publication. The present recommendation intends to provide guidance for the initial management of adult ALL patients and to define principles as a basis for future collaborative research.

Identifiants

pubmed: 38295337
pii: 514792
doi: 10.1182/blood.2023020794
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Nicola Gökbuget (N)

Goethe-Universität, Frankfurt, Germany.

Nicolas Boissel (N)

Hopital Saint-Louis, AP-HP, Paris, France.

Sabina Chiaretti (S)

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

Herve Dombret (H)

Université Paris Cité, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.

Michael Doubek (M)

Department of Internal Medicine - Hematology and Oncology, University Hospital Brno & Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Adele K Fielding (AK)

UCL Cancer Institute, London, United Kingdom.

Robin Foà (R)

Hematology, Department of Translational and Precision Medicine, Sapienza University, Italy., Rome, Italy.

Sebastian Giebel (S)

Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.

Dieter Hoelzer (D)

Goethe University, Germany.

David I Marks (DI)

University of Bristol, Bristol, United Kingdom.

Giovanni Martinelli (G)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Oliver G Ottmann (OG)

Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Anita W Rijneveld (AW)

Erasmus University Medical Center, Rotterdam, Netherlands.

Philippe Rousselot (P)

Centre Hospitalier de Versailles, Université Paris-Saclay, France.

Josep-Maria Ribera (JM)

Institut Català d'Oncologia-Hospital Germans Trias i Pujol. Josep Carreras Research Institute. Badalona. Universitat Autònoma de Barcelona, Badalona, Spain.

Renato Bassan (R)

Ospedale dell'Angelo, Mestre-Venezia, Mestre-Venezia, Italy.

Classifications MeSH